New hope for controlling scarred lungs in autoimmune disease patients
NCT ID NCT07319598
Summary
This study is testing whether adding a drug called tetrandrine to standard treatment can better control lung scarring in adults with connective tissue disease-related interstitial lung disease. About 100 participants will take either tetrandrine or a placebo pill for 24 weeks while continuing their usual medications. Researchers will measure changes in lung function, scans, and quality of life to see if the drug is safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.